PURPOSE OF REVIEW: The hypermetabolic response in critically ill patients is characterized by hyperdynamic circulatory, physiologic, catabolic and immune system responses. Failure to satisfy overwhelming energy and protein requirements after, and during critical illness, results in multiorgan dysfunction, increased susceptibility to infection, and death. Attenuation of the hypermetabolic response by various pharmacologic modalities is emerging as an essential component of the management of severe burn patients. This review focuses on the more recent advances in therapeutic strategies to attenuate the hypermetabolic response and its associated insulin resistance postburn. RECENT FINDINGS: At present, beta-adrenergic blockade with propranolol represents probably the most efficacious anticatabolic therapy in the treatment of burns. Other pharmacological strategies include growth hormone, insulin-like growth factor, oxandrolone and intensive insulin therapy. SUMMARY: Novel approaches to the management of critical illness by judicious glucose control and the use of pharmacologic modulators to the hypercatabolic response to critical illness have emerged. Investigation of alternative strategies, including the use of metformin, glucagon-like-peptide-1 and the PPAR-γ agonists are under current investigation.
PURPOSE OF REVIEW: The hypermetabolic response in critically illpatients is characterized by hyperdynamic circulatory, physiologic, catabolic and immune system responses. Failure to satisfy overwhelming energy and protein requirements after, and during critical illness, results in multiorgan dysfunction, increased susceptibility to infection, and death. Attenuation of the hypermetabolic response by various pharmacologic modalities is emerging as an essential component of the management of severe burn patients. This review focuses on the more recent advances in therapeutic strategies to attenuate the hypermetabolic response and its associated insulin resistance postburn. RECENT FINDINGS: At present, beta-adrenergic blockade with propranolol represents probably the most efficacious anticatabolic therapy in the treatment of burns. Other pharmacological strategies include growth hormone, insulin-like growth factor, oxandrolone and intensive insulin therapy. SUMMARY: Novel approaches to the management of critical illness by judicious glucose control and the use of pharmacologic modulators to the hypercatabolic response to critical illness have emerged. Investigation of alternative strategies, including the use of metformin, glucagon-like-peptide-1 and the PPAR-γ agonists are under current investigation.
Authors: G van den Berghe; P Wouters; F Weekers; C Verwaest; F Bruyninckx; M Schetz; D Vlasselaers; P Ferdinande; P Lauwers; R Bouillon Journal: N Engl J Med Date: 2001-11-08 Impact factor: 91.245
Authors: D W Hart; S E Wolf; R Mlcak; D L Chinkes; P I Ramzy; M K Obeng; A A Ferrando; R R Wolfe; D N Herndon Journal: Surgery Date: 2000-08 Impact factor: 3.982
Authors: Marc G Jeschke; Celeste C Finnerty; Gabriela A Kulp; Rene Przkora; Ronald P Mlcak; David N Herndon Journal: Pediatr Crit Care Med Date: 2008-03 Impact factor: 3.624
Authors: Jeffrey S Upperman; John C Bucuvalas; Felicia N Williams; Bruce A Cairns; Charles S Cox; Allan Doctor; Robert F Tamburro Journal: Pediatr Crit Care Med Date: 2017-03 Impact factor: 3.624
Authors: Silviu Constantin Badoiu; Daniela Miricescu; Iulia-Ioana Stanescu-Spinu; Alexandra Ripszky Totan; Silvia Elena Badoiu; Michel Costagliola; Maria Greabu Journal: Int J Mol Sci Date: 2021-05-13 Impact factor: 5.923